This podcast is brought to you by Outcomes Rocket, your exclusive healthcare marketing agency. Learn how to accelerate your growth by going to outcomesrocket.com
The crucial combination of human expertise and AI is paramount for success in drug development.
In this episode, Liesbeth Ceelen, CEO, and Arjan van Manen, Commercial Director of BioLizard, discuss the critical role of data analytics and machine learning in the pharmaceutical industry, highlighting the increasing need for companies to become data-driven. They emphasize how a deep understanding of biology, supported by AI, can optimize target discovery and reduce clinical trial failures. BioLizard offers the expertise and a platform to support biotech and pharma companies in this new data-driven approach as the industry shifts from viewing data analysis as a cost to a necessity for better outcomes. Finally, they touch upon predictions for 2025, focusing on a more data-supported approach to drug development, tailored treatments, and a heightened focus on target mechanisms while remaining optimistic about the changing mindset of industry stakeholders.
Tune in and learn how data analytics can transform your approach to drug development!
Resources:
- Connect and follow Liesbeth Ceelen on LinkedIn.
- Follow and connect with Arjan van Manen on LinkedIn.
- Follow BioLizard on LinkedIn and visit their website.
- Discover more about BioLizard’s platform, BioVerse, here.
Fast Track Your Business Growth:
Outcomes Rocket is a full service marketing agency focused on helping healthcare organizations like yours maximize your impact and accelerate growth. Learn more at outcomesrocket.com
[00:00:01] This podcast is produced by Outcomes Rocket, your healthcare exclusive digital marketing agency. Outcomes Rocket exists to help healthcare organizations like yours to maximize their impact and accelerate growth. Visit outcomesrocket.com or text us at 312-224-9945.
[00:00:30] Hey everyone, welcome back to the Outcomes Rocket here at the Biotech Showcase, live at the JP Morgan Health Conference in San Francisco. Today I have the privilege of hosting two amazing leaders in healthcare, Liesbeth Ceelen and Arjan van Manen. They are both with BioLizard. Liesbeth is the CEO and Arjan is the Commercial Director. I want to welcome you both to the podcast. Thank you. Thanks for joining me.
[00:00:57] Now let's kick it off by just sharing with our viewers and listeners what BioLizard does. So BioLizard is a data analytics and machine learning bioinformatics company. We support biotech and pharma companies to become more data driven. So we have an expert team of about 50 people with a strong skill set in bioinformatics, machine learning and so forth.
[00:01:22] And we also have a platform, bioinformatics. So we strongly focus on the human component and the AI component. That's beautiful. That's beautiful. That's beautiful. It sounds like very important work. And today, before we started recording, you guys were sharing with me the importance of technology in the development of new assets and new drugs. Can you share an insight that's risen to the top while at this conference or something that you've been thinking about for a while?
[00:03:19] What I also learned is that what I learned is that what it's really supporting our vision is a lot of clinical trials. It's 90 percent. But you really can reduce the failure or increase the success by adopting a more data driven approach. So I think that it's really important. And we're not there yet, but BioLizard is there to support companies to start thinking in that goal.
[00:03:42] That's fantastic. Really great to know. And something great for all of us to be thinking about in the development of new drugs, new assets for the market. What about predictions? You know, one thing we're asking our guests, predictions for 2025. What do you think this year holds for biotech? Well, I will do it first. So I think what you see is last year was challenging when it comes to the fundraise and really the growth of companies being supported.
[00:04:09] There's a lot more, I would say, attention to data supporting what you're claiming with the product to be able to achieve. And I think the services that we offer and the way that we approach data allows a new kind of like supporting evidence to generate that. And I think there will be a lot more requests coming in the industry to objectify kind of the claims that you have and how you're going to substantiate what you think drugs could achieve in patients.
[00:04:36] And it's not going to be blockbuster type of a purchase anymore. So you really need to have tailored approaches for a very specific mechanism of action. And I think the emphasis on target mechanism of action and treatment efficacy. And that's something that will be very dominant in the near future. Wow. Very interesting. What do you think? My predictions. I think it still will be a challenging year. The fundraising may go easier, but it won't be as before 23.
[00:05:06] What I noticed definitely during the conference that there was more that the mindset is changing. Like initially, definitely two years ago, last year even, they saw what we're doing often as a cost. Now people start realizing, I think we really should do it in order to be more successful during the clinical phases. So overall, I'm quite positive. That's great to hear. That's great to hear. Well, your work is fascinating.
[00:05:33] And certainly from its sounds, it's really helping organizations move forward in their efforts. The use of AI to really be more successful in the space. Where can people find your organization? Where can they find you if they want to learn more? First of all, yeah, they can look into our website. It's by lizard or lizard.bio, I must say. We are attending a lot of conferences. LinkedIn, definitely. Excellent.
[00:06:02] Overchall to one of us, right? Again, I think that's the use of it. Absolutely. So folks, we're going to have websites, LinkedIn profiles all in the show notes. So make sure you check them out. If something that we talked about today really resonated for you, make sure you check it out. Again, we've got Lisbeth Ceylon, CEO of BioLizard and Arjun Sanmanen. He is the commercial director at BioLizard. Check them out. And guys, thank you so much for doing that. 20 for the invitation, so.
[00:06:41] This podcast is produced by Outcomes Rocket, your healthcare exclusive digital marketing agency. Outcomes Rocket exists to help healthcare organizations like yours to maximize their impact and accelerate growth. Visit OutcomesRocket.com or text us at 312-224-9945.